Similar articles for PMID: 15709123

Year	Number of Results
1998	1
1999	1
2000	2
2001	1
2002	4
2003	2
2004	6
2005	7
2006	8
2007	2
2008	5
2009	8
2010	6
2011	9
2012	6
2013	6
2014	4
2015	6
2016	7
2017	11
2018	6
2019	3
2020	4
2021	5
2022	3
2023	1
2024	2

1

Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.

Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP. Cha S, et al. AJNR Am J Neuroradiol. 2005 Feb;26(2):266-73. AJNR Am J Neuroradiol. 2005. PMID: 15709123 Free PMC article.

2

Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.

Latysheva A, Emblem KE, Brandal P, Vik-Mo EO, Pahnke J, Røysland K, Hald JK, Server A. Latysheva A, et al. Neuroradiology. 2019 May;61(5):545-555. doi: 10.1007/s00234-019-02173-5. Epub 2019 Feb 2. Neuroradiology. 2019. PMID: 30712139

3

Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.

Abrigo JM, Fountain DM, Provenzale JM, Law EK, Kwong JS, Hart MG, Tam WWS. Abrigo JM, et al. Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2. Cochrane Database Syst Rev. 2018. PMID: 29357120 Free PMC article. Review.

4

Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR 4th, Fitzek MM, Chiocca EA, Rabinov JD, Csavoy AN, Rosen BR, Hochberg FH, Schaefer PW, Gonzalez RG. Lev MH, et al. AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21. AJNR Am J Neuroradiol. 2004. PMID: 14970020 Free PMC article.

5

Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease?

Bisdas S, Kirkpatrick M, Giglio P, Welsh C, Spampinato MV, Rumboldt Z. Bisdas S, et al. AJNR Am J Neuroradiol. 2009 Apr;30(4):681-8. doi: 10.3174/ajnr.A1465. Epub 2009 Jan 29. AJNR Am J Neuroradiol. 2009. PMID: 19179427 Free PMC article.

6

Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.

Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, Kelly PJ. Law M, et al. Neurosurgery. 2006 Jun;58(6):1099-107; discussion 1099-107. doi: 10.1227/01.NEU.0000215944.81730.18. Neurosurgery. 2006. PMID: 16723889

7

Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Law M, Young R, Babb J, Rad M, Sasaki T, Zagzag D, Johnson G. Law M, et al. AJNR Am J Neuroradiol. 2006 Oct;27(9):1975-82. AJNR Am J Neuroradiol. 2006. PMID: 17032878 Free PMC article.

8

Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response.

Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G. Law M, et al. Radiology. 2006 Feb;238(2):658-67. doi: 10.1148/radiol.2382042180. Epub 2006 Jan 5. Radiology. 2006. PMID: 16396838

9

Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.

Lee JY, Ahn KJ, Lee YS, Jang JH, Jung SL, Kim BS. Lee JY, et al. Acta Radiol. 2018 Jun;59(6):723-731. doi: 10.1177/0284185117728981. Epub 2017 Sep 1. Acta Radiol. 2018. PMID: 28862024

10

Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.

Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, Coons SW, Nakaji P, Yeh RF, Debbins J, Heiserman JE. Hu LS, et al. AJNR Am J Neuroradiol. 2009 Mar;30(3):552-8. doi: 10.3174/ajnr.A1377. Epub 2008 Dec 4. AJNR Am J Neuroradiol. 2009. PMID: 19056837 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year